EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Second Cancer Incidence and Cause‐Specific Mortality in Primary Gastrointestinal Non‐Hodgkin Lymphoma Survivors: A Population‐Based Cohort Study

Jiahe Wu, Jiangping Yang, Yuxi Ding, Jili Wang iD, Xiaofei Cheng, Liangshun You iD, Feng Zhao iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.71405 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Jiahe Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of Chi…. Hauptthemen laut MEDLINE: Neoplasms, Second Primary, Lymphoma, Non-Hodgkin, Gastrointestinal Neoplasms, Cancer Survivors. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Therapeutic advances in primary gastrointestinal non‐Hodgkin lymphoma (PGI‐NHL) have improved patient prognosis but also raised concerns regarding long‐term health outcomes. This study assesses patterns of second primary cancers (SPCs) and cause‐specific mortality in PGI‐NHL survivors.

Methods

A total of 7556 six‐month survivors of PGI‐NHL diagnosed between 1975 and 2015 were identified from the SEER database. SPC risks were evaluated using overall and site‐specific standardized incidence ratios (SIRs) and absolute excess risks (AERs) relative to the US general population. Cause‐specific mortality was assessed through proportional death distribution, the Fine–Gray competing risk regression model, standardized mortality ratios (SMRs), and AERs.

Results

During 75,914 person‐years of follow‐up, 1245 patients developed 1412 SPCs (SIR = 1.20, 95% CI = 1.14–1.27). Significantly elevated SIRs were observed for solid tumors (SIR = 1.16, 95% CI = 1.10–1.23) and hematolymphoid malignancies (SIR = 1.82, 95% CI = 1.49–2.19). Survivors with over 20 years of follow‐up faced increased risks of oral cavity and pharyngeal cancers (SIR = 2.76, 95% CI = 1.11–5.69), gastric cancer (SIR = 3.12, 95% CI = 1.15–6.80), pancreatic cancer (SIR = 2.40, 95% CI = 1.10–4.55), and leukemia (SIR = 2.57, 95% CI = 1.17–4.87). The risk of developing SPCs decreased with increasing age at PGI‐NHL diagnosis. Patients receiving combined chemoradiotherapy exhibited the highest overall SPC risk (SIR = 1.32, 95% CI = 1.09–1.58), particularly for gastric cancer (SIR = 8.20, 95% CI = 4.59–13.53) and pancreatic cancer (SIR = 3.15, 95% CI = 1.44–5.98). A total of 4949 deaths occurred (SMR = 1.80, 95% CI = 1.75–1.85), with excess mortality persisting beyond two decades. The cumulative incidence of all‐cause mortality was 28.9% at 5 years, 45.8% at 10 years, and 69.1% at 20 years post‐diagnosis. Non‐cancer causes posed a significant risk, with higher mortality from infections (SMR = 2.48, 95% CI = 2.22–2.76), chronic liver diseases (SMR = 1.72, 95% CI = 1.20–2.38), and benign/in situ neoplasms (SMR = 1.62, 95% CI = 1.05–2.38).

Conclusions

PGI‐NHL survivors face elevated long‐term SPC risk, particularly after chemoradiotherapy and in younger patients. Excess risks for both SPCs and mortality persist beyond two decades, necessitating lifelong, risk‐adapted survivorship care that includes cancer surveillance, infection prevention, and chronic comorbidity management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasms, Second PrimaryLymphoma, Non-HodgkinGastrointestinal NeoplasmsCancer SurvivorsHumansFemaleMaleMiddle AgedIncidenceAgedAdultSEER ProgramCause of DeathYoung AdultAged, 80 and overUnited StatesRisk FactorsCohort StudiesAdolescent

Stichwörter der Autor:innen

cause‐specific mortalityprimary gastrointestinal non‐Hodgkin lymphomasecond primary cancersstandardized incidence ratiostandardized mortality ratio

Autor:innen und Institutionen

  • Department of Radiation Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
  • Graduate School, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
  • Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education) of the Second Affiliated Hospital and Institute of Translational Medicine, Zhejiang University School of Medi…
  • Cancer Center of Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
  • School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.
  • Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.

ORCID-Profile: Jili Wang, Liangshun You, Feng Zhao

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wu, J., Yang, J., Ding, Y., Wang, J., Cheng, X., You, L., & Zhao, F. (2025). Second Cancer Incidence and Cause‐Specific Mortality in Primary Gastrointestinal Non‐Hodgkin Lymphoma Survivors: A Population‐Based Cohort Study. Cancer Medicine. https://doi.org/10.1002/cam4.71405

Vancouver

Wu J, Yang J, Ding Y, Wang J, Cheng X, You L, et al. Second Cancer Incidence and Cause‐Specific Mortality in Primary Gastrointestinal Non‐Hodgkin Lymphoma Survivors: A Population‐Based Cohort Study. Cancer Medicine. 2025. doi:10.1002/cam4.71405

BibTeX
@article{Wu2025,
  author = {Wu, Jiahe and Yang, Jiangping and Ding, Yuxi and Wang, Jili and Cheng, Xiaofei and You, Liangshun and Zhao, Feng},
  title = {Second Cancer Incidence and Cause‐Specific Mortality in Primary Gastrointestinal Non‐Hodgkin Lymphoma Survivors: A Population‐Based Cohort Study},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71405}
}
Kostenlos starten →